In clinical practice, anti-Ro/SSA antibodies can be associated with a wide range of SARDs, such as subacute cutaneous lupus, neonatal lupus, systemic lupus erythematous (SLE), SjS, SjS/SLE overlap syndrome, myositis, rheumatoid arthritis (RA) and primary biliary cirrhosis (24–28). This evidence concerns the gene TRIM21 and rheumatoid arthritis.